Shionogi demonstrates efficacy of cefiderocol against difficult-to-treat Gram-negative bacterial infections
Shionogi demonstrates efficacy of cefiderocol against difficult-to-treat Gram-negative bacterial infections At ECCMID 2023, Osaka, Japan-based Shionogi announced key data for cefiderocol, an innovative siderophore cephalosporin, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.